Promising preliminary results from trials enrolling patients with <i>EGFR</i>-mutated, <i>MET</i>amp advanced NSCLC progressing on an EGFR-tyrosine kinase inhibitor (TKI) were observed with MET-TKIs (i.e., tepotinib, savolitinib, and capmatinib) in combination with EGFR-TKIs (i.e., gefitinib and osimertinib). This evidence concerns the gene EGFR and non-small cell lung carcinoma.